TTD | Drug: D0C2OR

Drug General Information
Drug ID	D0C2OR
Former ID	DIB011124
Drug Name	MIM-D3
Synonyms	TrkA agonist (ocular disease/Alzheimer's disease), Mimetogen
Indication	Alzheimer disease [ICD9: 331; ICD10:G30]		Phase 3	[524465]
Company	Mimetogen Pharmaceuticals Inc
Structure		Download 2D MOL 3D MOL
Canonical SMILES	c12c(ccc(c1)[N+](=O)[O-])OCC[C@H](NC(=O)[C@@H](NC(=O)[C<br />@@H](NC2=O)CCC(=O)O)CCCCN)C(=O)NCC(=O)O
Target and Pathway
Target(s)	Neurotrophic tyrosine kinase receptor 1	Target Info	Agonist	[544321]
KEGG Pathway	MAPK signaling pathway
	Endocytosis
	Apoptosis
	Neurotrophin signaling pathway
	Inflammatory mediator regulation of TRP channels
	Pathways in cancer
	Transcriptional misregulation in cancer
	Thyroid cancer
	Central carbon metabolism in cancer
NetPath Pathway	IL2 Signaling Pathway
Pathway Interaction Database	Neurotrophic factor-mediated Trk receptor signaling
Reactome	Frs2-mediated activation
	ARMS-mediated activation
	NGF-independant TRKA activation
	PI3K/AKT activation
WikiPathways	MAPK Signaling Pathway
	BDNF signaling pathway
	Integrated Pancreatic Cancer Pathway
	NGF signalling via TRKA from the plasma membrane
References
Ref 524465	ClinicalTrials.gov (NCT01960010) A Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye. U.S. National Institutes of Health.
Ref 544321	Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye. Clin Ophthalmol. 2013; 7: 1275-1285.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Drug Information